Episode 358: 257. Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention

Episode 358: 257. Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention

https://www.nejm.org/doi/full/10.1056/NEJMoa2407001


Conclusions

No participants receiving twice-yearly lenacapavir acquired HIV infection. HIV incidence with lenacapavir was significantly lower than background HIV incidence and HIV incidence with F/TDF.



Among 5338 participants who were initially HIV-negative, 55 incident HIV infections were observed: 0 infections among 2134 participants in the lenacapavir group (0 per 100 person-years; 95% confidence interval [CI], 0.00 to 0.19), 39 infections among 2136 participants in the F/TAF group (2.02 per 100 person-years; 95% CI, 1.44 to 2.76), and 16 infections among 1068 participants in the F/TDF group (1.69 per 100 person-years; 95% CI, 0.96 to 2.74)

Episoder(387)

Populært innen Helse

fastlegen
lydartikler-fra-aftenposten
rss-gukild-johaug
hvordan-har-du-det-mann
psykodrama
relasjonspodden-med-dora-thorhallsdottir-kjersti-idem
leger-om-livet
rss-garne-damer
foreldreradet
hjernesterk
hormonelle-frida
rss-lopedrommen
bak-fasaden-en-reise-i-livet-med-sykepleier-ine
morten-ramm-lar-kakla-ga-til-du-sovner
klimaks
rss-kull
g-punktet
rss-sunn-okonomi
sinnsyn
helsetipspodden